BRAF and melanoma: The following drugs were tested: glutaminase inhibitor CB-839 as an indirect inhibitor of TCA, monocarboxylate transporter (MCT) inhibitor diclofenac as an indirect inhibitor of glycolysis [26], metformin as a complex I inhibitor and vemurafenib as a prominent targeted treatment for BRAF-mutated melanoma, which is reported to lead to a switch to mitochondrial respiration in sensitive cells [27].